Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.

Animals Apolipoproteins E Atherosclerosis / etiology Cell Culture Techniques Dipeptidyl-Peptidase IV Inhibitors / therapeutic use Disease Models, Animal Endothelial Cells / drug effects Endothelium, Vascular / drug effects Mice Mice, Inbred C57BL Vascular Cell Adhesion Molecule-1 / blood Vildagliptin / therapeutic use
Atherosclerosis Diabetes mellitus Endothelial function GLP-1

Journal

International heart journal
ISSN: 1349-3299
Titre abrégé: Int Heart J
Pays: Japan
ID NLM: 101244240

Informations de publication

Date de publication:
30 Nov 2019
Historique:
pubmed: 19 11 2019
medline: 18 12 2019
entrez: 19 11 2019
Statut: ppublish

Résumé

Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel antidiabetic agents with possible vascular protection effects. Endothelial dysfunction is an initiation step in atherogenesis. The purpose of this study was to investigate whether vildagliptin (Vilda) attenuates the development of endothelial dysfunction and atherosclerotic lesions in nondiabetic apolipoprotein E-deficient (ApoE

Identifiants

DOI: 10.1536/ihj.19-117 PMID: 31735774
pubmed: 31735774
doi: 10.1536/ihj.19-117
doi:

Substances chimiques

Apolipoproteins E 0
Dipeptidyl-Peptidase IV Inhibitors 0
Vascular Cell Adhesion Molecule-1 0
Vildagliptin I6B4B2U96P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1421-1429

Auteurs

Kunduziayi Aini (K)

Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences.

Daiju Fukuda (D)

Department of Cardio-Diabetes Medicine, Tokushima University Graduate School of Biomedical Science.

Kimie Tanaka (K)

Division for Health Service Promotion, The University of Tokyo.

Yasutomi Higashikuni (Y)

Department of Cardiovascular Medicine, The University of Tokyo.

Yoichiro Hirata (Y)

Department of Pediatrics, The University of Tokyo Hospital.

Shusuke Yagi (S)

Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences.

Kenya Kusunose (K)

Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences.

Hirotsugu Yamada (H)

Department of Community Medicine for Cardiology, Tokushima University Graduate School of Biomedical Sciences.

Takeshi Soeki (T)

Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences.

Masataka Sata (M)

Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Apolipoprotéines › Apolipoprotéines E › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Artériopathies oblitérantes › Artériosclérose › Athérosclérose › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Techniques d'investigation › Techniques in vitro › Techniques de culture › Techniques de culture cellulaire › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Inhibiteurs de la dipeptidyl-peptidase IV › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules endothéliales › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Tissus › Épithélium › Endothélium › Endothélium vasculaire › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes de surface › Molécules d'adhérence cellulaire › Molécule-1 d'adhérence des cellules vasculaires › Vildagliptin, a DPP-4 Inhibitor, Attenuates...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrrolidines › Vildagliptine › Vildagliptin, a DPP-4 Inhibitor, Attenuates...